REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.8 HKD | -0.67% |
|
-2.30% | -20.43% |
| 04-26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 39,166 | 31,092 | 36,877 | 28,299 | 24,763 | - | - |
| Enterprise Value (EV) 1 | 36,595 | 29,387 | 34,808 | 28,741 | 25,771 | 26,814 | 27,746 |
| P/E ratio | -56.1 x | 111 x | -27.2 x | -11.9 x | -13.1 x | -22 x | -57.7 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 21.8 x | 48 x | 26.1 x | 14.6 x | 9.49 x | 7.49 x |
| EV / Revenue | - | 20.6 x | 45.3 x | 26.5 x | 15.2 x | 10.3 x | 8.39 x |
| EV / EBITDA | -60.4 x | 80.3 x | -43.8 x | -21.7 x | -28.2 x | -40.9 x | 256 x |
| EV / FCF | -33.2 x | -83.6 x | -17.2 x | -12.2 x | -18.4 x | -36.1 x | -134 x |
| FCF Yield | -3.02% | -1.2% | -5.8% | -8.2% | -5.44% | -2.77% | -0.75% |
| Price to Book | 10.9 x | 8.98 x | 3.64 x | 5.34 x | 5.17 x | 6.76 x | 8.57 x |
| Nbr of stocks (in thousands) | 489,837 | 489,837 | 539,197 | 538,532 | 537,914 | - | - |
| Reference price 2 | 79.96 | 63.47 | 51.14 | 34.04 | 27.61 | 27.61 | 27.61 |
| Announcement Date | 26/03/21 | 20/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,426 | 767.8 | 1,083 | 1,690 | 2,609 | 3,307 |
| EBITDA 1 | - | -605.6 | 365.8 | -794.1 | -1,322 | -915.4 | -655.2 | 108.4 |
| EBIT 1 | - | -668.6 | 281.6 | -980.9 | -1,502 | -907.6 | -215.3 | 84.5 |
| Operating Margin | - | - | 19.74% | -127.76% | -138.65% | -53.69% | -8.25% | 2.56% |
| Earnings before Tax (EBT) 1 | - | -697.8 | 276.3 | -998.8 | -1,511 | -1,152 | -683.4 | -279.7 |
| Net income 1 | -430.3 | -697.8 | 276.3 | -998.8 | -1,511 | -1,148 | -687.3 | -270.7 |
| Net margin | - | - | 19.37% | -130.09% | -139.55% | -67.89% | -26.35% | -8.19% |
| EPS 2 | - | -1.425 | 0.5700 | -1.880 | -2.860 | -2.113 | -1.254 | -0.4787 |
| Free Cash Flow 1 | - | -1,104 | -351.4 | -2,019 | -2,356 | -1,402 | -743.4 | -207 |
| FCF margin | - | - | -24.64% | -263% | -217.51% | -82.91% | -28.5% | -6.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 28/10/20 | 26/03/21 | 20/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales | - | 1,397 | - | - | 198.1 | 419 | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | 720.3 | - | - | - | -509.7 | - |
| Net income 1 | -444 | - | -489.1 | -199.1 | - | -509.7 | -323.8 |
| Net margin | - | - | - | - | - | -121.65% | - |
| EPS 2 | -0.9100 | - | -0.9600 | -0.3600 | - | - | -0.6000 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 23/08/21 | 20/02/22 | 30/08/22 | 27/10/22 | 27/02/23 | 27/02/23 | 27/04/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 442 | 1,008 | 2,051 | 2,983 |
| Net Cash position 1 | - | 2,571 | 1,704 | 2,069 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3342 x | -1.101 x | -3.13 x | 27.52 x |
| Free Cash Flow 1 | - | -1,104 | -351 | -2,019 | -2,356 | -1,402 | -743 | -207 |
| ROE (net income / shareholders' equity) | - | -41.5% | 7.85% | -23.7% | -35.5% | -38.9% | -37.4% | -25.1% |
| ROA (Net income/ Total Assets) | - | -29% | 6.68% | -19.6% | -26.2% | -19.9% | -11.9% | -6.48% |
| Assets 1 | - | 2,403 | 4,138 | 5,090 | 5,775 | 5,770 | 5,789 | 4,177 |
| Book Value Per Share 2 | - | 7.340 | 7.070 | 14.00 | 6.380 | 5.340 | 4.080 | 3.220 |
| Cash Flow per Share 2 | - | -1.620 | 0.5400 | -2.380 | - | -1.740 | -0.5100 | -0.1000 |
| Capex 1 | - | 443 | 615 | 756 | 853 | 516 | 332 | 242 |
| Capex / Sales | - | - | 43.12% | 98.41% | 78.74% | 30.54% | 12.73% | 7.32% |
| Announcement Date | 28/10/20 | 26/03/21 | 20/02/22 | 27/02/23 | 23/02/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
27.61
CNY
Average target price
39.69
CNY
Spread / Average Target
+43.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.43% | 3.42B | |
| -1.43% | 104B | |
| +8.96% | 105B | |
| +4.40% | 22.94B | |
| -12.15% | 22.34B | |
| -4.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- 9995 Stock
- Financials RemeGen Co., Ltd.
